ReviewGM crops & food2026
An evaluation of the returns to biotech canola considering health, production and environmental externalities.
Review in GM crops & food, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rising health care cost in Canada and other developed countries, as well as the pressure for climate change mitigation, reflects the importance of consumption and production-related externalities in agriculture. This study assesses the economic returns to the biotech canola industry in Canada, considering potential health care savings and greenhouse gas (GHG) emissions reduction associated with canola oil consumption and canola seed production. It is shown that the indirect benefits of consumption and production-related externalities associated with the canola sector are substantial aspects of the gains from agricultural research investments and the impacts of agriculture policy. Our estimates suggest that the external implications of increased canola production and consumption could exceed 20% of the economic effect of biotechnological improvements in canola. The impact on research policy and improvement in overall social welfare are also discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.